Truqap is a kinase inhibitor that works by blocking pathways that assist the cancer cells endure and grow, so minimizes cancer progress. Truqap is from a category of medicines named an AKT inhibitor. Truqap gained FDA acceptance on November 17, 2023, after good final results from your CAPItello-291 Stage III https://trastuzumabderuxtecan13578.blogsuperapp.com/35365865/the-5-second-trick-for-capivasertib